

For Immediate Release

Net Profit up 154%, Net Revenues up 54%

Vadodara April 27th, 2016

Alembic Pharmaceuticals Limited reported its audited financial results for the year ending 31st March 2016.

Financial Highlights

- Net Sales up 54% to Rs. 3181 crores
- Net Profit up 154% to Rs. 719 crores

Commenting on the results, Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said "This has been an outstanding year for the Company. R&D will continue to remain a thrust area and we hope to strengthen our portfolio rapidly in the years to come. The recent JV with Orbicular will help establish our presence in the dermatology segment".

Operational Highlights for the year

International Formulations

- International formulation business grew 146% to Rs. 1462 crores
- Alembic USA office set up and 11 products launched on own label
- 8 ANDA applications filed, Cumulative ANDA filings at 76
- 9 DMF applications filed, Cumulative DMF filings at 81
- JV with Orbicular for Dermatology

ALEMBIC PHARMACEUTICALS LIMITED

India Branded Formulations

- Sikkim plant commissioned
- India Branded formulations grew 13% to Rs. 1104 crore
- Specialty segment grew 20%
 - Cardiology up 36%
 - Anti Diabetic up 34%
 - Gynaecology up 25%

Dividend

The Board has recommended dividend on equity shares at Rs. 4.00 per share i.e. 200% for 15-16 (P.Y. Rs. 3.50 per share i.e. 175%)

Summary of Total Revenue is as under:

(Rs in Lacs)

Particulars	Q4 FY16	Q4 FY15	% Change	FY16	FY15	% Change
Formulation						
International	19018	15835	20%	146150	59348	146%
India Branded	25963	23208	12%	110357	98084	13%
India Generics	1744	3209	-46%	9118	12274	-26%
API	16691	8543	95%	52494	37067	42%
Total	63416	50795	25%	318119	206773	54%

ALEMBIC PHARMACEUTICALS LIMITED

The Profit break-up is as under:

(Rs in Lacs)

Particulars	Q4 FY16	Q4 FY15	% Change	FY16	FY15	% Change
EBITDA	14330	9795	46%	100598	40297	150%
Profit Before Tax	12022	8848	36%	93560	35908	161%
Net Profit after Tax	9118	7033	30%	71944	28293	154%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com;
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai	Mitanshu Shah
Phone: +91 22 – 306 11681	Phone: +91 265 – 3007630
Email: ajay.desai@alembic.co.in	Email: mitanshu.shah@alembic.co.in

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
www.alembic-india.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123